Encyclopedia of Signaling Molecules

2012 Edition
| Editors: Sangdun Choi

TPD52 (Tumor Protein D52)

  • Austin Della-Franca
  • Yuyan Chen
  • Jennifer Anne Byrne
Reference work entry
DOI: https://doi.org/10.1007/978-1-4419-0461-4_555

Synonyms

Historical Background and Overview

Mammalian TPD52 sequences were first reported in the mid-1990s, through a number of independent approaches. Two early reports identified TPD52 sequences through their increased expression in human cancer tissue or cell lines, relative to either nonmalignant tissues or fibroblast cell lines. Orthologous sequences from other species were identified as proteins phosphorylated in response to increased intracellular calcium, or as a retroviral target gene. Early reports also highlighted the existence of paralogous sequences in human and mouse, and TPD52 is now known to be part of a four-member mammalian gene family. While TPD52-like sequences are well conserved both within and between species, they show little homology with those of other proteins.

Human TPD52 isoforms are approximately 200 residues in length,...
This is a preview of subscription content, log in to check access.

References

  1. Boutros R, Fanayan S, Shehata M, Byrne JA. The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun. 2004;325:1115–21.PubMedGoogle Scholar
  2. Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, et al. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010;10:497.PubMedGoogle Scholar
  3. Chew CS, Chen X, Zhang H, Berg EA, Zhang H. Calcium/calmodulin-dependent phosphorylation of tumor protein D52 on serine residue 136 may be mediated by CAMK2delta6. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1159–72.PubMedGoogle Scholar
  4. Dutertre M, Gratadou L, Dardenne E, Germann S, Samaan S, Lidereau R, et al. Estrogen regulation and physiopathologic significance of alternative promoters in breast cancer. Cancer Res. 2010;70:3760–70.PubMedGoogle Scholar
  5. Kourtidis A, Jain R, Carkner RD, Eifert C, Brosnan MJ, Conklin DS. An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature. Cancer Res. 2010;70:1783–92.PubMedGoogle Scholar
  6. Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother. 2009;58:1337–49.PubMedGoogle Scholar
  7. Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, et al. PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol Carcinog. 2009;48:432–40.PubMedGoogle Scholar
  8. Mattison J, Kool J, Uren AG, de Ridder J, Wessels L, Jonkers J, et al. Novel candidate cancer genes identified by a large-scale cross-species comparative oncogenomics approach. Cancer Res. 2010;70:883–95.PubMedGoogle Scholar
  9. Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, et al. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine. 2009;27:1825–33.PubMedGoogle Scholar
  10. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121:575–89.PubMedGoogle Scholar
  11. Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother. 2008;57:799–811.PubMedGoogle Scholar
  12. Shehata M, Weidenhofer J, Thamotharampillai K, Hardy JR, Byrne JA. Tumor protein D52 overexpression and gene amplification in cancers from a mosaic of microarrays. Crit Rev Oncog. 2008;14:33–55.PubMedGoogle Scholar
  13. Thomas DD, Martin CL, Weng N, Byrne JA, Groblewski GE. Tumor protein D52 expression and Ca2+−dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane. Am J Physiol Cell Physiol. 2010;298:C725–39.PubMedGoogle Scholar
  14. Ummanni R, Teller S, Junker H, Zimmermann U, Venz S, Scharf C, et al. Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 2008;275:5703–13.PubMedGoogle Scholar
  15. Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res. 2007;6:3962–75.PubMedGoogle Scholar
  16. Zhao P, Zhong W, Ying X, Yao B, Yuan Z, Fu J, et al. Comparative proteomic analysis of anti-benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide-transformed and normal human bronchial epithelial G0/G1 cells. Chem Biol Interact. 2010;186:166–73.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Austin Della-Franca
    • 1
  • Yuyan Chen
    • 1
  • Jennifer Anne Byrne
    • 1
  1. 1.Children’s Cancer Research Unit, Kids Research InstituteThe Children’s Hospital at WestmeadWestmeadAustralia